Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)

Key facts

Sponsor

Merck Sharp & Dohme LLC

Principal Investigator

Medical Director

Merck Sharp & Dohme LLC

Intervention

Ramucirumab(biological)

Enrollment

210 enrolled

Eligibility

18 years · All sexes

Timeline

2024 – 2030

Study locations (30)

• University of Arizona Cancer Center-University of Arizona Cancer Center ( Site 8927), Tucson, Arizona, United States
• UCLA Hematology/Oncology - Santa Monica ( Site 8905), Los Angeles, California, United States
• Norton Cancer Institute - Downtown ( Site 8900), Louisville, Kentucky, United States
• The Cancer and Hematology Centers ( Site 8912), Grand Rapids, Michigan, United States
• Hematology-Oncology Associates of Central NY, P.C. ( Site 8925), East Syracuse, New York, United States
• Columbia University Irving Medical Center-CUIMC Herbert Irving Comprehensive Cancer Center Clinical ( Site 8907), New York, New York, United States
• UPMC Hillman Cancer Center-UPMC ( Site 8904), Pittsburgh, Pennsylvania, United States
• University of Texas MD Anderson Cancer Center ( Site 8920), Houston, Texas, United States
• Liga Norte Riograndense Contra o Câncer ( Site 8303), Natal, Rio Grande do Norte, Brazil
• Hospital Nossa Senhora da Conceição ( Site 8301), Porto Alegre, Rio Grande do Sul, Brazil
• IBCC - Instituto Brasileiro de Controle do Câncer ( Site 8304), São Paulo, São Paulo, Brazil
• Clínica Puerto Montt ( Site 8409), Port Montt, Los Lagos Region, Chile
• Centro de Investigación del Maule ( Site 8408), Talca, Maule Region, Chile
• FALP-UIDO ( Site 8400), Santiago, Region M. de Santiago, Chile
• Centro de Oncología de Precisión-Oncology ( Site 8404), Santiago, Region M. de Santiago, Chile
• +15 more locations on ClinicalTrials.gov

Collaborators

Daiichi Sankyo

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Adenocarcinoma of the oesophagus and oesophagogastric junction

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT07432295
  Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
  I-Mab Biopharma US Limited
• RECRUITINGPHASE1NCT07059299
  A Phase Ib Trial Evaluating the Safety and Activity of Neoadjuvant Combination of Tislelizumab Plus FLOT for Resectable Esophagogastric Adenocarcinoma
  Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
• RECRUITINGPHASE1NCT07284186
  First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
  Plexium, Inc.
• RECRUITINGPHASE2NCT06161818
  Total Neoadjuvant Therapy for Lymph Node-positive Adenocarcinoma of the OESophagus and Oesophagogastric Junction
  Erasmus Medical Center
• RECRUITINGPHASE2NCT06628310
  A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
  AbbVie
• RECRUITINGPHASE2NCT05563766
  A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer
  VA Office of Research and Development
• RECRUITINGNANCT06649474
  Evaluation, in Humans, of the Correlation Between Hepatotoxicity, Neurotoxicity Induced by Oxaliplatin, and Blood Levels of HMGB1
  University Hospital, Clermont-Ferrand
• RECRUITINGPHASE1, PHASE2NCT06324357
  Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
  Boehringer Ingelheim

See all trials for Adenocarcinoma of the oesophagus and oesophagogastric junction →